Ronald M. Lindsay
Amministratore Delegato presso Zebra Biologics, Inc.
Profilo
Ronald M.
Lindsay was the founder of Neurocentrx Pharma Ltd.
founded in 2008, where he served as Executive Chairman from 2008 to 2013.
Currently, he holds the position of Chairman & Chief Executive Officer at Zebra Biologics, Inc., and Director at HistoRx, Inc. and Depixus SAS.
Dr. Lindsay has previously worked as a Director at ArQule, Inc., Neuro3D SA, and Sequenom, Inc. where he served as Director from 2003 to 2016.
He has also worked as Vice President-Neurobiology at Regeneron Pharmaceuticals, Inc. from 1989 to 1997, Senior Vice President-Biotherapeutics at Millennium Pharmaceuticals, Inc. from 1997 to 2000, and CSO, Vice President-Research & Development at diaDexus, Inc. from 2000 to 2004.
Additionally, he has worked as Head-Cell Biology at Sandoz Institute for Medical Research from 1984 to 1989.
Dr. Lindsay has an undergraduate degree from the University of Glasgow and a doctorate from the University of Calgary.
Posizioni attive di Ronald M. Lindsay
| Società | Posizione | Inizio |
|---|---|---|
HistoRx, Inc.
 HistoRx, Inc. Medical SpecialtiesHealth Technology HistoRx, Inc. develops tissue-based diagnostic products. The company was founded on July 23, 2004 and is headquartered in Carlsbad, CA. | Direttore/Membro del Consiglio | - |
Zebra Biologics, Inc.
 Zebra Biologics, Inc. Pharmaceuticals: MajorHealth Technology Zebra Biologics, Inc. is a biotechnology company that specializes in developing bio superior antibody therapeutics and complex drug targets. The private company is based in Concord, MA. Zebra Biologics was founded by Richard Alan Lerner and the CEO is Ronald M. Lindsay. | Amministratore Delegato | - |
Depixus SAS
 Depixus SAS Miscellaneous Commercial ServicesCommercial Services Depixus SAS is a life science technology company based in Paris, France. Depixus is pioneering ground-breaking magna™ technology based on magnetic force spectroscopy, revealing dramatic new insights into complex biomolecular interactions at the single molecule level. The French company was founded by Gordon Hamilton and has been the CEO since incorporation. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Ronald M. Lindsay
| Società | Posizione | Fine |
|---|---|---|
| SEQUENOM, INC. | Presidente | 21/12/2009 |
Neuro3D SA
 Neuro3D SA Pharmaceuticals: OtherHealth Technology Neuro3d SA develops pharmaceutical products to treat the central nervous system. Neuro3d has a full pipeline of innovative compounds with new mechanisms of action that have the potential to overcome the limitations of current drug therapies. It leads compound, the atypical antipsychotic ocaperidone, is being investigated in two international double-blind Phase II trials for treatment of schizophrenia. The company was founded in November 2000 and is headquartered in Mulhouse, France. | Direttore/Membro del Consiglio | 21/10/2013 |
Neurocentrx Pharma Ltd.
 Neurocentrx Pharma Ltd. Pharmaceuticals: MajorHealth Technology Neurocentrx Pharma Ltd. is a British pharmaceutical company that manufactures and distributes medicines. The company is based in Edinburgh, UK. Neurocentrx Pharma was founded by Howard Marriage, Ronald M. Lindsay, and Carmel Reilly. Carmel Reilly has been the CEO since incorporation. | Fondatore | 01/01/2013 |
diaDexus, Inc. /Old/
 diaDexus, Inc. /Old/ Medical SpecialtiesHealth Technology diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field. | Direttore Tecnico/Scientifico/R&S | 01/01/2004 |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/01/2000 |
Formazione di Ronald M. Lindsay
| University of Glasgow | Undergraduate Degree |
| University of Calgary | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| REGENERON PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 10 |
|---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
ArQule, Inc.
 ArQule, Inc. Pharmaceuticals: MajorHealth Technology ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company was founded in 1993 and is headquartered in Burlington, MA. | Health Technology |
Sequenom, Inc.
 Sequenom, Inc. Medical SpecialtiesHealth Technology Sequenom, Inc. engages in the provision of early patient management information. It develops and commercializes molecular diagnostic testing services that serve women's health and oncology markets. The company was founded by Hubert Koester and Charles R. Cantor in October 09, 1996 and is headquartered in Burlington, NC. | Health Technology |
diaDexus, Inc. /Old/
diaDexus, Inc. /Old/ Medical SpecialtiesHealth Technology diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field. | Health Technology |
Zebra Biologics, Inc.
Zebra Biologics, Inc. Pharmaceuticals: MajorHealth Technology Zebra Biologics, Inc. is a biotechnology company that specializes in developing bio superior antibody therapeutics and complex drug targets. The private company is based in Concord, MA. Zebra Biologics was founded by Richard Alan Lerner and the CEO is Ronald M. Lindsay. | Health Technology |
Neuro3D SA
Neuro3D SA Pharmaceuticals: OtherHealth Technology Neuro3d SA develops pharmaceutical products to treat the central nervous system. Neuro3d has a full pipeline of innovative compounds with new mechanisms of action that have the potential to overcome the limitations of current drug therapies. It leads compound, the atypical antipsychotic ocaperidone, is being investigated in two international double-blind Phase II trials for treatment of schizophrenia. The company was founded in November 2000 and is headquartered in Mulhouse, France. | Health Technology |
HistoRx, Inc.
HistoRx, Inc. Medical SpecialtiesHealth Technology HistoRx, Inc. develops tissue-based diagnostic products. The company was founded on July 23, 2004 and is headquartered in Carlsbad, CA. | Health Technology |
| Sandoz Institute for Medical Research | |
Neurocentrx Pharma Ltd.
Neurocentrx Pharma Ltd. Pharmaceuticals: MajorHealth Technology Neurocentrx Pharma Ltd. is a British pharmaceutical company that manufactures and distributes medicines. The company is based in Edinburgh, UK. Neurocentrx Pharma was founded by Howard Marriage, Ronald M. Lindsay, and Carmel Reilly. Carmel Reilly has been the CEO since incorporation. | Health Technology |
Depixus SAS
Depixus SAS Miscellaneous Commercial ServicesCommercial Services Depixus SAS is a life science technology company based in Paris, France. Depixus is pioneering ground-breaking magna™ technology based on magnetic force spectroscopy, revealing dramatic new insights into complex biomolecular interactions at the single molecule level. The French company was founded by Gordon Hamilton and has been the CEO since incorporation. | Commercial Services |
- Borsa valori
- Insiders
- Ronald M. Lindsay
